Clinical Trials

This section contains references to information on clinical trials related to carcinoid cancer and neuroendocrine tumors. This section may not represent an inclusive list of all clinical trials that are in process or being planned worldwide.

• Clinical Trials.gov (Specifically for carcinoid/NETs) 

The U.S. National Institutes of Health, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members and members of the public current information about clinical research studies.

For additional clinical trials contact the NCI's Cancer Information service at 800-422-6237

• Please visit North American NeuroEndocrine Tumor Society (NANETS)

For current clinical trials:  http://nanets.net/research/articles/current-clinical-trials

• Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

• Health Familial Carcinoid Cancer Study
  Natural History of Familial Carcinoid Tumor

This study is currently recruiting participants. 

Verified by National Institutes of Health Clinical Center (CC), March 2008

No results have been posted on this study.

• Lithium for Low-Grade Neuroendocrine Tumors. This study has been completed.

Location and Contact Information:

Please refer to this study by ClinicalTrials.gov identifier  NCT00501540

United States, Wisconsin
University of Wisconsin
Paul P. Carbone Comprehensive Cancer Center 
Madison, Wisconsin 53792
United States

Recruiting Cancer Connect  800-622-8922  
Kelly Richie  608-263-7283  
Kyle D Holen, MD,  Principal Investigator

Study chairs or principal investigators:
Kyle D Holen, MD,  Principal Investigator,  University of Wisconsin Paul P. Carbone Comprehensive Cancer Center    
Herbert Chen, MD,  Study Chair,  University of Wisconsin Paul P. Carbone Comprehensive Cancer Center 

For more information, click here.

• This Study has been completed -- No results have been posted on this study

Callisto Pharmaceuticals Opens First Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

http://www.clinicaltrials.gov/ct/show/NCT00388063?order=2

This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma (Carcinoid/NET) who have metastatic or unresectable local-regional cancer and who have either symptoms ( diarrhea, flushing adn/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s).

Contact Information:
Craig C Talluto, PhD, abd 212-297-0010 Ext. 231 
Cathy Clare, R.N. 212-207-0010 Ext. 234 

Website

• Now recruiting

University of California, San Francisco (UCSF) Comprehensive Cancer Center - Clinical Trial

Chemotherapy drugs like 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) work in different ways to cause tumor cells to stop growing or die. Bevacizumab is a monoclonal antibody that may inhibit cancer growth by blocking blood flow to tumors. Adding bevacizumab to combination chemotherapy may be a better way to block tumor growth than giving either type of therapy alone. The FOLFOX plus bevacizumab combination is being studied in patients with neuroendocrine tumors because FOLFOX appears to inhibit the growth of a variety of different tumor types but has not yet been tested in this disease. In addition, neuroendocrine tumors appear to depend on blood vessels for growth suggesting that they may respond to a treatment like bevacizumab. This clinical trial is for patients who have not responded to other treatments to see if the FOLFOX/bevacizumab combination is safe and if it can inhibit the growth of metastatic neuroendocrine tumors.

LOCATION AND CONTACT INFORMATION

Clinical Trials Recruitment Nurse
UCSF Comprehensive Cancer Center
Clinical Research Support Services
1600 Divisadero Street
San Francisco, CA 94115

Tel: (415) 353-9612
Fax: (415) 353-9738